Frederick R. Ueland, MD

Chief, Division of Gynecologic Oncology
Vice Chair, Department of Obstetrics and Gynecology
Fellowship Director

Clinical interests

  • Advanced Chemotherapy and Clinical Trials
  • Minimally Invasive Surgery
  • Ovarian Cancer Surgery
  • Ovarian Tumor Ultrasound
  • Pelvic Surgery

Frederick R. Ueland, MD

Chief, Division of Gynecologic Oncology
Vice Chair, Department of Obstetrics and Gynecology
Fellowship Director

Biography

My name is Frederick Ueland; I am a graduate of Stanford University and received my medical degree from the Wake Forest University, School of Medicine, Winston-Salem, N.C. I then completed a fellowship in Gynecologic Oncology at the University of Kentucky, Lexington. I am board certified by the American Board of Obstetrics and Gynecology in Gynecologic Oncology.

My special interests include ovarian tumor evaluation with ultrasound and biomarkers, treatment of ovarian cancer, and advanced pelvic surgery. I am an active translational researcher at the NCI-designated Markey Cancer Center, and was the principal investigator for the OVA-1 trial which resulted in FDA-clearance for the ovarian tumor blood test in 2009. I am also the Medical Director of Gynecologic Surgery, and Medical Director of Outpatient Chemotherapy and Infusion for UK HealthCare. I serve on a number of local and national cancer committees.

Faculty rank

Professor of Obstetrics and Gynecology

Education

Degree
Wake Forest University, School of Medicine, Winston-Salem, N.C.

Residency
University of Kentucky, Lexington

Fellowship
University of Kentucky, Lexington

Certifications or Special training
American Board of Obstetrics and Gynecology
American Board of Obstetrics and Gynecology, Gynecologic Oncology

Gynecologic Oncology

Gynecologic Oncology Clinic

Markey Cancer Center
Whitney-Hendrickson Building
Third Floor, Room 330A
740 Rose St.
Lexington KY 40536-0098

Call 859-323-5553
Call 866-340-4488
Fax 859-323-1602

Directions to Markey Cancer Center - Whitney-Hendrickson Building »


UK HealthCare accepts many forms of insurance. See list of insurers »

 
  1. Matsuo K, Takazawa Y, Ross MS, Elishaev E, Podzielinski I, Yunokawa M, Sheridan TB, Bush SH, Klobocista MM, Blake EA, Takano T, Matsuzaki S, Baba T, Satoh S, Shida M, Nishikawa T, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Fujiwara K, Hazama Y, Kadogami D, Moffitt MN, Takeuchi S, Nishimura M, Iwasaki K, Ushioda N, Johnson MS, Yoshida M, Hakam A, Li SW, Richmond AM, Machida H, Mhawech-Fauceglia P, Ueda Y, Yoshino K, Yamaguchi K, Oishi T, Kajiwara H, Hasegawa K, Yasuda M, Kawana K, Suda K, Miyake TM, Moriya T, Yuba Y, Morgan T, Fukagawa T, Wakatsuki A, Sugiyama T, Pejovic T, Nagano T, Shimoya K, Andoh M, Shiki Y, Enomoto T, Sasaki T, Fujiwara K, Mikami M, Shimada M, Konishi I, Kimura T, Post MD, Shahzad MM, Im DD, Yoshida H, Omatsu K, Ueland FR, Kelley JL, Karabakhtsian RG, Roman LD. Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma. Ann Oncol. 2016 Jul;27(7):1257-66.
    View in: PubMed
  2. Lefringhouse JR, Neward E, Ueland FR, Baldwin LA, Miller RW, DeSimone CP, Kryscio RJ, van Nagell JR, Pavlik EJ. Probability of fallopian tube and ovarian detection with transvaginal ultrasonography in normal women. Womens Health (Lond). 2016 Jun;12(3):303-11.
    View in: PubMed
  3. Baldwin LA, Hoff JT, Lefringhouse J, Zhang M, Jia C, Liu Z, Erfani S, Jin H, Xu M, She QB, van Nagell JR, Wang C, Chen L, Plattner R, Kaetzel DM, Luo J, Lu M, West D, Liu C, Ueland FR, Drapkin R, Zhou BP, Yang XH. CD151-α3β1 integrin complexes suppress ovarian tumor growth by repressing slug-mediated EMT and canonical Wnt signaling. Oncotarget. 2014 Dec 15;5(23):12203-17.
    View in: PubMed
  4. Elder JW, Pavlik EJ, Long A, Miller RW, DeSimone CP, Hoff JT, Ueland WR, Kryscio RJ, van Nagell JR, Ueland FR. Serial ultrasonographic evaluation of ovarian abnormalities with a morphology index. Gynecol Oncol. 2014 Oct;135(1):8-12.
    View in: PubMed
  5. Goodrich ST, Bristow RE, Santoso JT, Miller RW, Smith A, Zhang Z, Ueland FR. The effect of ovarian imaging on the clinical interpretation of a multivariate index assay. Am J Obstet Gynecol. 2014 Jul;211(1):65.e1-65.e11.
    View in: PubMed
  6. Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, DeSimone CP, Ueland FR, van Nagell JR, Seamon LG. Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol. 2012 Sep; 120(3):612-8. PMID: 22914471.
    View in: PubMed
  7. McDonald JM, Karabakhtsian RG, Pierce HH, Iocono JA, Desimone CP, Bayliff SL, Ueland FR. Small cell carcinoma of the ovary of hypercalcemic type: a case report. J Pediatr Surg. 2012 Mar; 47(3):588-92. PMID: 22424359.
    View in: PubMed
  8. Miller RW, Ueland FR. Risk of malignancy in sonographically confirmed ovarian tumors. Clin Obstet Gynecol. 2012 Mar; 55(1):52-64. PMID: 22343229.
    View in: PubMed
  9. van Nagell JR, Miller RW, DeSimone CP, Ueland FR, Podzielinski I, Goodrich ST, Elder JW, Huang B, Kryscio RJ, Pavlik EJ. Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening. Obstet Gynecol. 2011 Dec; 118(6):1212-21. PMID: 22105249.
    View in: PubMed
  10. Ueland FR, Desimone CP, Seamon LG, Miller RA, Goodrich S, Podzielinski I, Sokoll L, Smith A, van Nagell JR, Zhang Z. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol. 2011 Jun; 117(6):1289-97. PMID: 21606739.
    View in: PubMed
  11. Ware Miller R, Smith A, DeSimone CP, Seamon L, Goodrich S, Podzielinski I, Sokoll L, van Nagell JR, Zhang Z, Ueland FR. Performance of the American College of Obstetricians and Gynecologists' ovarian tumor referral guidelines with a multivariate index assay. Obstet Gynecol. 2011 Jun; 117(6):1298-306. PMID: 21555961.
    View in: PubMed
  12. Saunders BA, Podzielinski I, Ware RA, Goodrich S, DeSimone CP, Ueland FR, Seamon L, Ubellacker J, Pavlik EJ, Kryscio RJ, van Nagell JR. Risk of malignancy in sonographically confirmed septated cystic ovarian tumors. Gynecol Oncol. 2010 Sep; 118(3):278-82. PMID: 20554314.
    View in: PubMed
  13. Powell MA, Filiaci VL, Rose PG, Mannel RS, Hanjani P, Degeest K, Miller BE, Susumu N, Ueland FR. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. J Clin Oncol. 2010 Jun 1; 28(16):2727-31. PMID: 20421537.
    View in: PubMed
  14. McDonald JM, Doran S, DeSimone CP, Ueland FR, DePriest PD, Ware RA, Saunders BA, Pavlik EJ, Goodrich S, Kryscio RJ, van Nagell JR. Predicting risk of malignancy in adnexal masses. Obstet Gynecol. 2010 Apr; 115(4):687-94. PMID: 20308826.
    View in: PubMed
  15. Makhija S, Amler LC, Glenn D, Ueland FR, Gold MA, Dizon DS, Paton V, Lin CY, Januario T, Ng K, Strauss A, Kelsey S, Sliwkowski MX, Matulonis U. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol. 2010 Mar 1; 28(7):1215-23. PMID: 19901115.
    View in: PubMed
  16. Pavlik EJ, Saunders BA, Doran S, McHugh KW, Ueland FR, Desimone CP, Depriest PD, Ware RA, Kryscio RJ, van Nagell JR. The search for meaning-Symptoms and transvaginal sonography screening for ovarian cancer: predicting malignancy. Cancer. 2009 Aug 15; 115(16):3689-98. PMID: 19603478.
    View in: PubMed
  17. Desimone CP, Ueland FR. Gynecologic laparoscopy. Surg Clin North Am. 2008 Apr; 88(2):319-41, vi. PMID: 18381116.
    View in: PubMed
  18. van Nagell JR, DePriest PD, Ueland FR, DeSimone CP, Cooper AL, McDonald JM, Pavlik EJ, Kryscio RJ. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer. 2007 May 1; 109(9):1887-96. PMID: 17373668.
    View in: PubMed
  19. Homesley HD, Filiaci V, Markman M, Bitterman P, Eaton L, Kilgore LC, Monk BJ, Ueland FR. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 Feb 10; 25(5):526-31. PMID: 17290061.
    View in: PubMed
  20. Dietrich CS, Desimone CP, Modesitt SC, Depriest PD, Ueland FR, Pavlik EJ, Kryscio R, Cibull M, Huh W, Partridge E, Numnum TM, Schilder J, Higgins RV, van Nagell JR. Primary appendiceal cancer: gynecologic manifestations and treatment options. Gynecol Oncol. 2007 Mar; 104(3):602-6. PMID: 17055559.
    View in: PubMed
  21. DeSimone CP, Van Ness JS, Cooper AL, Modesitt SC, DePriest PD, Ueland FR, Pavlik EJ, Kryscio RJ, van Nagell JR. The treatment of lateral T1 and T2 squamous cell carcinomas of the vulva confined to the labium majus or minus. Gynecol Oncol. 2007 Feb; 104(2):390-5. PMID: 17027067.
    View in: PubMed
  22. DeSimone CP, Crisp MP, Ueland FR, DePriest PD, van Nagell JR, Lele SM, Modesitt SC. Concordance of gross surgical and final fixed margins in vulvar intraepithelial neoplasia 3 and vulvar cancer. J Reprod Med. 2006 Aug; 51(8):617-20. PMID: 16967630.
    View in: PubMed
  23. Disis ML, Rivkin SE, Baron A, Markman M, Connolly D, Ueland F, Kohn E, Trimble E, Berek JS. Progress in ovarian cancer research: proceedings of the 5th Biennial Ovarian Cancer Research Symposium. Int J Gynecol Cancer. 2006 Mar-Apr; 16(2):463-9. PMID: 16681712.
    View in: PubMed
  24. Dietrich CS, Modesitt SC, DePriest PD, Ueland FR, Wilder J, Reedy MB, Pavlik EJ, Kryscio R, Cibull M, Giesler J, Manahan K, Huh W, Cohn D, Powell M, Slomovitz B, Higgins RV, Merritt W, Hunter J, Puls L, Gehrig P, van Nagell JR. The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). Gynecol Oncol. 2005 Dec; 99(3):557-63. PMID: 16154185.
    View in: PubMed
  25. Ueland FR, Depriest PD, Desimone CP, Pavlik EJ, Lele SM, Kryscio RJ, van Nagell JR. The accuracy of examination under anesthesia and transvaginal sonography in evaluating ovarian size. Gynecol Oncol. 2005 Nov; 99(2):400-3. PMID: 16084576.
    View in: PubMed
  26. Wilder JL, Shajahan S, Khattar NH, Wilder DM, Yin J, Rushing RS, Beaven R, Kaetzel C, Ueland FR, van Nagell JR, Kryscio RJ, Lele SM. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study. Gynecol Oncol. 2004 Feb; 92(2):553-8. PMID: 14766247.
    View in: PubMed
  27. Rushing RS, Shajahan S, Chendil D, Wilder JL, Pulliam J, Lee EY, Ueland FR, van Nagell JR, Ahmed MM, Lele SM. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT. Gynecol Oncol. 2003 Oct; 91(1):9-14. PMID: 14529657.
    View in: PubMed
  28. Ueland FR, DePriest PD, Pavlik EJ, Kryscio RJ, van Nagell JR. Preoperative differentiation of malignant from benign ovarian tumors: the efficacy of morphology indexing and Doppler flow sonography. Gynecol Oncol. 2003 Oct; 91(1):46-50. PMID: 14529661.
    View in: PubMed
  29. Modesitt SC, Pavlik EJ, Ueland FR, DePriest PD, Kryscio RJ, van Nagell JR. Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. Obstet Gynecol. 2003 Sep; 102(3):594-9. PMID: 12962948.
    View in: PubMed
  30. Wilder JL, Pavlik E, Straughn JM, Kirby T, Higgins RV, DePriest PD, Ueland FR, Kryscio RJ, Whitley RJ, Nagell Jv. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecol Oncol. 2003 May; 89(2):233-5. PMID: 12713985.
    View in: PubMed
  31. Schilder JM, Thompson AM, DePriest PD, Ueland FR, Cibull ML, Kryscio RJ, Modesitt SC, Lu KH, Geisler JP, Higgins RV, Magtibay PM, Cohn DE, Powell MA, Chu C, Stehman FB, van Nagell J. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol. 2002 Oct; 87(1):1-7. PMID: 12468335.
    View in: PubMed
  32. Pavlik EJ, Liu C, DePriest PD, Gallion HH, Ueland FR, Kryscio RJ, van Nagell JR. Relating ovarian size to age, menopausal status, and use of hormones. Gynecol Oncol. 2001 Feb; 80(2):333-4. PMID: 11161877.
    View in: PubMed
  33. van Nagell JR, DePriest PD, Reedy MB, Gallion HH, Ueland FR, Pavlik EJ, Kryscio RJ. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol. 2000 Jun; 77(3):350-6. PMID: 10831341.
    View in: PubMed
  34. Pavlik EJ, DePriest PD, Gallion HH, Ueland FR, Reedy MB, Kryscio RJ, van Nagell JR. Ovarian volume related to age. Gynecol Oncol. 2000 Jun; 77(3):410-2. PMID: 10831351.
    View in: PubMed
  35. Reedy MB, Richards WE, Ueland F, Uy K, Lee EY, Bryant C, van Nagell JR. Ovarian steroid cell tumors, not otherwise specified: a case report and literature review. Gynecol Oncol. 1999 Nov; 75(2):293-7. PMID: 10525390.
    View in: PubMed
  36. van Nagell JR, Ueland FR. Ultrasound evaluation of pelvic masses: predictors of malignancy for the general gynecologist. Curr Opin Obstet Gynecol. 1999 Feb; 11(1):45-9. PMID: 10047963.
    View in: PubMed
  37. Bailey CL, Ueland FR, Land GL, DePriest PD, Gallion HH, Kryscio RJ, van Nagell JR. The malignant potential of small cystic ovarian tumors in women over 50 years of age. Gynecol Oncol. 1998 Apr; 69(1):3-7. PMID: 9570990.
    View in: PubMed
  38. Buckley SL, Tritz DM, Van Le L, Higgins R, Sevin BU, Ueland FR, DePriest PD, Gallion HH, Bailey CL, Kryscio RJ, Fowler W, Averette H, van Nagell JR. Lymph node metastases and prognosis in patients with stage IA2 cervical cancer. Gynecol Oncol. 1996 Oct; 63(1):4-9. PMID: 8898159.
    View in: PubMed
  39. Ferguson JE, Ueland FR, Stevenson DK, Ueland K. Oxytocin-induced labor characteristics and uterine activity after preinduction cervical priming with prostaglandin E2 intracervical gel. Obstet Gynecol. 1988 Nov; 72(5):739-45. PMID: 3173925.
    View in: PubMed
  40. Ueland K, McAnulty JH, Ueland FR, Metcalfe J. Special considerations in the use of cardiovascular drugs. Clin Obstet Gynecol. 1981 Sep; 24(3):809-23. PMID: 7026105.
    View in: PubMed